MXPA97009275A - Use of derivatives of sulfamic acid, acil sulfonamides or sulfonil carbamates for the manufacture of a medicinal product to reduce delipoprotei levels - Google Patents
Use of derivatives of sulfamic acid, acil sulfonamides or sulfonil carbamates for the manufacture of a medicinal product to reduce delipoprotei levelsInfo
- Publication number
- MXPA97009275A MXPA97009275A MXPA/A/1997/009275A MX9709275A MXPA97009275A MX PA97009275 A MXPA97009275 A MX PA97009275A MX 9709275 A MX9709275 A MX 9709275A MX PA97009275 A MXPA97009275 A MX PA97009275A
- Authority
- MX
- Mexico
- Prior art keywords
- methylethyl
- bis
- phenyl
- sulfamic acid
- phenyl ester
- Prior art date
Links
- -1 acil sulfonamides Chemical class 0.000 title claims description 269
- IIACRCGMVDHOTQ-UHFFFAOYSA-N Sulfamic acid Chemical class NS(O)(=O)=O IIACRCGMVDHOTQ-UHFFFAOYSA-N 0.000 title claims description 85
- 229940093912 Gynecological Sulfonamides Drugs 0.000 title description 3
- 229940079867 intestinal antiinfectives Sulfonamides Drugs 0.000 title description 3
- 238000004519 manufacturing process Methods 0.000 title description 3
- 229940005938 ophthalmologic antiinfectives Sulfonamides Drugs 0.000 title description 3
- 229940026752 topical Sulfonamides Drugs 0.000 title description 3
- 150000004657 carbamic acid derivatives Chemical class 0.000 title description 2
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims abstract description 118
- 125000000217 alkyl group Chemical group 0.000 claims abstract description 65
- 150000001875 compounds Chemical class 0.000 claims abstract description 45
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract description 34
- 239000001257 hydrogen Substances 0.000 claims abstract description 34
- 125000000753 cycloalkyl group Chemical group 0.000 claims abstract description 27
- 229910052760 oxygen Inorganic materials 0.000 claims abstract description 23
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 claims abstract description 23
- 239000001301 oxygen Substances 0.000 claims abstract description 23
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims abstract description 11
- 229910052717 sulfur Inorganic materials 0.000 claims abstract description 11
- 239000011593 sulfur Substances 0.000 claims abstract description 11
- 201000001084 cerebrovascular disease Diseases 0.000 claims abstract description 9
- 125000001624 naphthyl group Chemical group 0.000 claims abstract description 9
- 125000003710 aryl alkyl group Chemical group 0.000 claims abstract description 8
- 125000005073 adamantyl group Chemical group C12(CC3CC(CC(C1)C3)C2)* 0.000 claims abstract description 7
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims abstract description 7
- 125000004435 hydrogen atoms Chemical group [H]* 0.000 claims abstract description 7
- 206010034636 Peripheral vascular disease Diseases 0.000 claims abstract description 6
- 230000001225 therapeutic Effects 0.000 claims abstract description 4
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 117
- 125000004432 carbon atoms Chemical group C* 0.000 claims description 70
- 239000007983 Tris buffer Substances 0.000 claims description 49
- 125000003545 alkoxy group Chemical group 0.000 claims description 22
- 125000000218 acetic acid group Chemical group C(C)(=O)* 0.000 claims description 20
- 150000002431 hydrogen Chemical class 0.000 claims description 20
- 150000003839 salts Chemical class 0.000 claims description 15
- 239000011780 sodium chloride Substances 0.000 claims description 15
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 13
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 claims description 12
- WKBOTKDWSSQWDR-UHFFFAOYSA-N bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 claims description 12
- 239000000460 chlorine Substances 0.000 claims description 12
- 229910052801 chlorine Inorganic materials 0.000 claims description 12
- ZAMOUSCENKQFHK-UHFFFAOYSA-N chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 claims description 12
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 12
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 12
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 12
- 125000001424 substituent group Chemical group 0.000 claims description 12
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 12
- 125000002915 carbonyl group Chemical group [*:2]C([*:1])=O 0.000 claims description 11
- 210000002381 Plasma Anatomy 0.000 claims description 10
- 125000004423 acyloxy group Chemical group 0.000 claims description 9
- 229910052736 halogen Inorganic materials 0.000 claims description 9
- 150000002367 halogens Chemical class 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 125000000472 sulfonyl group Chemical group *S(*)(=O)=O 0.000 claims description 8
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 7
- SWYZGLWCQFMQJW-UHFFFAOYSA-N phenoxy hypofluorite Chemical compound FOOC1=CC=CC=C1 SWYZGLWCQFMQJW-UHFFFAOYSA-N 0.000 claims description 7
- 200000000008 restenosis Diseases 0.000 claims description 6
- 125000001637 1-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C(*)=C([H])C([H])=C([H])C2=C1[H] 0.000 claims description 5
- 125000001622 2-naphthyl group Chemical group [H]C1=C([H])C([H])=C2C([H])=C(*)C([H])=C([H])C2=C1[H] 0.000 claims description 5
- LSBDFXRDZJMBSC-UHFFFAOYSA-N 2-phenylacetamide Chemical compound NC(=O)CC1=CC=CC=C1 LSBDFXRDZJMBSC-UHFFFAOYSA-N 0.000 claims description 5
- PCVSBMWYSWVMGR-UHFFFAOYSA-N OC1=CC=CC=C1OF Chemical compound OC1=CC=CC=C1OF PCVSBMWYSWVMGR-UHFFFAOYSA-N 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- KXDHJXZQYSOELW-UHFFFAOYSA-M carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 claims description 5
- 210000002966 Serum Anatomy 0.000 claims description 4
- 159000000000 sodium salts Chemical class 0.000 claims description 4
- IBHZMFUKPWDNEH-UHFFFAOYSA-N [2-[2,4-di(propan-2-yl)-3-sulfamoyloxyphenyl]-2-oxo-1-[2,4,6-tri(propan-2-yl)phenyl]ethyl] acetate Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C(OC(C)=O)C(=O)C1=CC=C(C(C)C)C(OS(N)(=O)=O)=C1C(C)C IBHZMFUKPWDNEH-UHFFFAOYSA-N 0.000 claims description 3
- SDPAXONVAAUGHV-UHFFFAOYSA-N 2-phenyl-2-sulfonylacetamide Chemical compound NC(=O)C(=S(=O)=O)C1=CC=CC=C1 SDPAXONVAAUGHV-UHFFFAOYSA-N 0.000 claims description 2
- FFHDHZYMGPGQLF-UHFFFAOYSA-N [2,6-di(propan-2-yl)-3-[2-[2,4,6-tri(propan-2-yl)phenoxy]acetyl]phenyl] sulfamate Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1OCC(=O)C1=CC=C(C(C)C)C(OS(N)(=O)=O)=C1C(C)C FFHDHZYMGPGQLF-UHFFFAOYSA-N 0.000 claims description 2
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 2
- 230000036470 plasma concentration Effects 0.000 claims description 2
- 229910052708 sodium Inorganic materials 0.000 claims description 2
- 239000011734 sodium Substances 0.000 claims description 2
- 241000124008 Mammalia Species 0.000 claims 5
- SVISWFVZGCSHEK-UHFFFAOYSA-N 2-[2,6-di(propan-2-yl)phenyl]-N-[[2,4,6-tri(propan-2-yl)phenyl]methylsulfonyl]acetamide Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1CS(=O)(=O)NC(=O)CC1=C(C(C)C)C=CC=C1C(C)C SVISWFVZGCSHEK-UHFFFAOYSA-N 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- DDHOUTXDEJOEFF-UHFFFAOYSA-N [3-[2-fluoro-2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]-2,6-di(propan-2-yl)phenyl] sulfamate Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C(F)C(=O)C1=CC=C(C(C)C)C(OS(N)(=O)=O)=C1C(C)C DDHOUTXDEJOEFF-UHFFFAOYSA-N 0.000 claims 1
- UVDBZLKUTRQIEF-UHFFFAOYSA-N [3-[2-hydroxy-2-[2,4,6-tri(propan-2-yl)phenyl]acetyl]-2,6-di(propan-2-yl)phenyl] sulfamate Chemical compound CC(C)C1=CC(C(C)C)=CC(C(C)C)=C1C(O)C(=O)C1=CC=C(C(C)C)C(OS(N)(=O)=O)=C1C(C)C UVDBZLKUTRQIEF-UHFFFAOYSA-N 0.000 claims 1
- 125000003668 acetyloxy group Chemical group [H]C([H])([H])C(=O)O[*] 0.000 claims 1
- OKTJSMMVPCPJKN-UHFFFAOYSA-N carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims 1
- 229910052799 carbon Inorganic materials 0.000 claims 1
- 125000003074 decanoyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C(*)=O 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- HVYWMOMLDIMFJA-DPAQBDIFSA-N (3β)-Cholest-5-en-3-ol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 16
- 102100001083 LPA Human genes 0.000 description 15
- 108010007622 LDL Lipoproteins Proteins 0.000 description 10
- 102000007330 LDL Lipoproteins Human genes 0.000 description 10
- 108010033266 Lipoprotein(a) Proteins 0.000 description 10
- 102000013566 Plasminogen Human genes 0.000 description 9
- 108010051456 Plasminogen Proteins 0.000 description 9
- 229940107161 Cholesterol Drugs 0.000 description 8
- 101700086454 LPA Proteins 0.000 description 8
- 239000002585 base Substances 0.000 description 8
- 235000012000 cholesterol Nutrition 0.000 description 8
- 239000003795 chemical substances by application Substances 0.000 description 5
- 235000013305 food Nutrition 0.000 description 5
- 241001465754 Metazoa Species 0.000 description 4
- 102000004169 proteins and genes Human genes 0.000 description 4
- 108090000623 proteins and genes Proteins 0.000 description 4
- 206010003210 Arteriosclerosis Diseases 0.000 description 3
- 208000006011 Stroke Diseases 0.000 description 3
- 201000001320 atherosclerosis Diseases 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 230000000302 ischemic Effects 0.000 description 3
- 238000000034 method Methods 0.000 description 3
- 241000282693 Cercopithecidae Species 0.000 description 2
- 206010010904 Convulsion Diseases 0.000 description 2
- 102000033147 ERVK-25 Human genes 0.000 description 2
- 210000002889 Endothelial Cells Anatomy 0.000 description 2
- 108091005771 Peptidases Proteins 0.000 description 2
- 239000004365 Protease Substances 0.000 description 2
- 206010039911 Seizure Diseases 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 230000037213 diet Effects 0.000 description 2
- 235000005911 diet Nutrition 0.000 description 2
- 229940079593 drugs Drugs 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 2
- 125000001183 hydrocarbyl group Chemical group 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 150000007970 thio esters Chemical class 0.000 description 2
- ZMANZCXQSJIPKH-UHFFFAOYSA-N triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 2
- COVZYZSDYWQREU-UHFFFAOYSA-N 1,4-Butanediol, dimethanesulfonate Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
- 125000000579 2,2-diphenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C1=C([H])C([H])=C([H])C([H])=C1[H])C([H])([H])* 0.000 description 1
- 125000004974 2-butenyl group Chemical group C(C=CC)* 0.000 description 1
- 125000003890 2-phenylbutyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000003903 2-propenyl group Chemical group [H]C([*])([H])C([H])=C([H])[H] 0.000 description 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 108010071619 Apolipoproteins Proteins 0.000 description 1
- 102000007592 Apolipoproteins Human genes 0.000 description 1
- 102000018616 Apolipoproteins B Human genes 0.000 description 1
- 108010027006 Apolipoproteins B Proteins 0.000 description 1
- 210000004369 Blood Anatomy 0.000 description 1
- HQPSKTOGFFYYKN-UHFFFAOYSA-N CC(C)[Na] Chemical class CC(C)[Na] HQPSKTOGFFYYKN-UHFFFAOYSA-N 0.000 description 1
- 206010008118 Cerebral infarction Diseases 0.000 description 1
- 108091007140 Cholesterol transporters Proteins 0.000 description 1
- JQVDAXLFBXTEQA-UHFFFAOYSA-N Dibutylamine Chemical compound CCCCNCCCC JQVDAXLFBXTEQA-UHFFFAOYSA-N 0.000 description 1
- 102100015239 F2 Human genes 0.000 description 1
- 108010080865 Factor XII Proteins 0.000 description 1
- 102000000429 Factor XII Human genes 0.000 description 1
- RGHNJXZEOKUKBD-SQOUGZDYSA-N Gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 108010010234 HDL Lipoproteins Proteins 0.000 description 1
- 102000015779 HDL Lipoproteins Human genes 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 208000009576 Hypercholesterolemia Diseases 0.000 description 1
- 238000008214 LDL Cholesterol Methods 0.000 description 1
- 102000004895 Lipoproteins Human genes 0.000 description 1
- 108090001030 Lipoproteins Proteins 0.000 description 1
- PCZOHLXUXFIOCF-BXMDZJJMSA-N Lovastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)[C@@H](C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 PCZOHLXUXFIOCF-BXMDZJJMSA-N 0.000 description 1
- 241000282567 Macaca fascicularis Species 0.000 description 1
- 229920002521 Macromolecule Polymers 0.000 description 1
- 229940053207 Niacin Drugs 0.000 description 1
- 230000036823 Plasma Levels Effects 0.000 description 1
- 108010094028 Prothrombin Proteins 0.000 description 1
- 229940039716 Prothrombin Drugs 0.000 description 1
- YGSDEFSMJLZEOE-UHFFFAOYSA-N Salicylic acid Chemical compound OC(=O)C1=CC=CC=C1O YGSDEFSMJLZEOE-UHFFFAOYSA-N 0.000 description 1
- 210000003752 Saphenous Vein Anatomy 0.000 description 1
- RYMZZMVNJRMUDD-HGQWONQESA-N Simvastatin Chemical compound C([C@H]1[C@@H](C)C=CC2=C[C@H](C)C[C@@H]([C@H]12)OC(=O)C(C)(C)CC)C[C@@H]1C[C@@H](O)CC(=O)O1 RYMZZMVNJRMUDD-HGQWONQESA-N 0.000 description 1
- 102000003978 Tissue plasminogen activator Human genes 0.000 description 1
- 108090000373 Tissue plasminogen activator Proteins 0.000 description 1
- 229960005356 Urokinase Drugs 0.000 description 1
- 102000003990 Urokinase-type plasminogen activator Human genes 0.000 description 1
- 108090000435 Urokinase-type plasminogen activator Proteins 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000003670 adamantan-2-yl group Chemical group [H]C1([H])C(C2([H])[H])([H])C([H])([H])C3([H])C([*])([H])C1([H])C([H])([H])C2([H])C3([H])[H] 0.000 description 1
- 230000001058 adult Effects 0.000 description 1
- 150000001412 amines Chemical class 0.000 description 1
- 239000003529 anticholesteremic agent Substances 0.000 description 1
- 230000000890 antigenic Effects 0.000 description 1
- 238000002617 apheresis Methods 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid group Chemical group C(C1=CC=CC=C1)(=O)O WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 235000021152 breakfast Nutrition 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 210000004027 cells Anatomy 0.000 description 1
- 229940112021 centrally acting muscle relaxants Carbamic acid esters Drugs 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 238000007887 coronary angioplasty Methods 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 description 1
- 125000000640 cyclooctyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 description 1
- 230000003247 decreasing Effects 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 230000003480 fibrinolytic Effects 0.000 description 1
- 239000003527 fibrinolytic agent Substances 0.000 description 1
- 238000005755 formation reaction Methods 0.000 description 1
- 230000002068 genetic Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 150000004679 hydroxides Chemical class 0.000 description 1
- 239000002471 hydroxymethylglutaryl coenzyme A reductase inhibitor Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 230000003993 interaction Effects 0.000 description 1
- 230000002452 interceptive Effects 0.000 description 1
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 description 1
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 description 1
- 239000002655 kraft paper Substances 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- WHXSMMKQMYFTQS-UHFFFAOYSA-N lithium Chemical compound [Li] WHXSMMKQMYFTQS-UHFFFAOYSA-N 0.000 description 1
- 229910052744 lithium Inorganic materials 0.000 description 1
- 229960004844 lovastatin Drugs 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 235000012054 meals Nutrition 0.000 description 1
- 125000003136 n-heptyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 125000001280 n-hexyl group Chemical group C(CCCCC)* 0.000 description 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- DFPAKSUCGFBDDF-UHFFFAOYSA-N nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 230000003000 nontoxic Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 125000003538 pentan-3-yl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])C([H])([H])[H] 0.000 description 1
- 125000004115 pentoxy group Chemical group [*]OC([H])([H])C([H])([H])C([H])([H])C(C([H])([H])[H])([H])[H] 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- 230000004977 physiological function Effects 0.000 description 1
- 230000035790 physiological processes and functions Effects 0.000 description 1
- 229940096701 plain lipid modifying drugs HMG CoA reductase inhibitors Drugs 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 230000002028 premature Effects 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 229960002855 simvastatin Drugs 0.000 description 1
- 235000012177 snack cakes Nutrition 0.000 description 1
- KEAYESYHFKHZAL-UHFFFAOYSA-N sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 1
- 200000000009 stenosis Diseases 0.000 description 1
- 230000036262 stenosis Effects 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 description 1
- 230000002588 toxic Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 150000003626 triacylglycerols Chemical class 0.000 description 1
- JOYRKODLDBILNP-UHFFFAOYSA-N urethane group Chemical group NC(=O)OCC JOYRKODLDBILNP-UHFFFAOYSA-N 0.000 description 1
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
- 230000003442 weekly Effects 0.000 description 1
Abstract
The present invention relates to: It leads to new therapeutic uses of the compounds of Formula (I) wherein X and Y are oxygen, sulfur or (CR'R ") n where n is 1 to 4, R is hydrogen, alkyl or benzyl; R1 and R2 are phenyl, substituted phenyl, naphthyl, substituted naphthyl, an aralkyl group, an alkyl, adamantyl or a cycloalkyl group. The uses are for cerebrovascular diseases such as attacks, peripheral vascular diseases and restenos
Description
USE OF DERIVATIVES OF SULPHAMIC ACID, ACIL SULFONAMIDES OR SULFONIL CARBAMATES FOR THE MANUFACTURE OF A
MEDICATION TO DECREASE LEVELS OF LIPOPROTEINS
BACKGROUND OF THE INVENTION The compounds of the present invention are described fully in the
Copending application of the United States with serial number 08 / 223,932 filed on April 13, 1994. The use of the compounds shown is hypercholesterolemia and atherosclerosis. This application is incorporated herein by reference.
The compounds of the copending application increased chemical stability over those of U.S. Patent No. 5, 254,068.
The present invention relates generally to lipoprotein (a), Lp (a) and more particularly to the methods and agents for lowering its plasma concentrations to achieve a therapeutic benefit.
The macromolecule known as lipoprotein (a), or Lp (a), is a low density lipoprotein (LDL) complex and a hydrophilic glycoprotein that has been given the name of apoliprotein (a), or apo (a). The main LDL protein is apo B-l 00 and apo (a) binds to the apo B half of LDL via a sulfide bond. LDL is the largest cholesterol transporter in human plasma. The physiological function of Lp (a) is unknown.
Apo (a) is not structurally similar to other apolipoproteins, but exhibits similarity to another plasma protein called plasminogen. The structure of the plasminogen includes five homologous domains repeated together called kringles (Kringles I - V) which are pretzel-like structures stabilized by three internal disulfide bridges followed by a protease domain. Kringle structures have been identified in several other proteins such as prothrombin, tissue-type plasminogen activator (t -PA), urokinase and coagulation factor XII (Utermann, Science, 1989; 246: 904-910).
Apo (a) lacks similar Kringles from I to III of the plasminogen, but has multiple copies of the Kringle domain similar to the plasminogen quarter and a single copy of a Kringle domain similar to the fifth of plasminogen (Kringle-5). Apo (a) also contains a protease domain.
Lp (a) was first identified by Berg in 1963 (Berg, Acta Pathol, Microbiol Scand., 1963; 59: 369) as an antigenic activity associated with the LDL fraction in the plasma of some individuals. Plasma Lp (a) levels vary in different individuals from less than 2 mg / dL to more than 200 mg / dL. Increased plasma levels of Lp (a) are considered to be a risk factor for atherosclerosis, either alone or in combination with elevated LDL levels (Kostner, et al., Circulation, 1989; 80 (5): 1313- 1319 citing previous researchers). The concentration of Lp (a) in the plasma and the size of Apo (a) are determined genetically (Gavish, et al., J. Clin Invest., 1989; 84: 2021-2027).
The discovery of the homology of apo (a) to plasminogen, has led to further investigations as the role played by Lp (a). Hajjar, et al., Nature, 1989; 339: 303-305 considers the similarity between the apo (a) component of Lp (a) and plasminogen and investigates the effect that Lp (a) could have on the interaction between plasminogen and the endothelial cell and found that Lp (a) ) competes for plasminogen binding sites and appears to be able to inhibit the activation of plasminogens on the surface of endothelial cells by t - PA. This suggests that high levels of Lp (a) could impair and inhibit fibrinolysis of the cell surface, interfering in this way with the fibrinolytic system. In Kostner, et al., (See above), the HMG-CoA reductase inhibitors such as simvastatin and lovastatin, as well as other known cholesterol lowering agents are administered to a group of test patients and then, the samples of plasma are taken and examined. Most of the tested agents failed at lower levels of Lp (a) and, in fact, in some cases, Lp (a) levels appear to increase, possibly due to the stimulation of Lp (a) production. The authors identified only two agents, namely, neomycin and niacin, which lower LDL and Lp levels
(to). These agents only diminish Lp (a) to a limit to such a degree and due to this, as well as to the lateral toxic effects, it does not seem to present a viable therapeutic avenue.
Therefore, there is a need for an effective method and associated agents to decrease the levels of Lp (a) in the plasma.
The role of lipoprotein (a) has been studied in patients suffering from ischemic cerebrovascular disease and it has been determined that they have significantly higher levels of lipoprotein (a), lipid transporters by intermediate density proteins, low protein cholesterol density and lower levels of high density lipoproteins than the control subjects. These are, then, factors of greater risk for ischemic cerebrovascular disease (Pedro-Botck, Stroke, 1992; 23 (11): 1556-1562).
Lipoprotein (a) is a genetic risk factor, independent and critical for ischemic attack, especially in young adults (Nagayama, Stroke, 1994; 25 (1):
74-78).
High levels of lipoprotein (a) in serum are an independent risk factor in the development of cerebral infarction (Shintani, Stroke, 1993; 24 (7): 965-969.
Elevated levels of lipoprotein Lp (a) in plasma have been linked to the development of premature atherosclerosis in the coronary circulation (Valentine, Arch. Intern. Med., 1994; 154: 801-806).
The prevention of restenosis after percutaneous transluminal coronary angioplasty by reducing lipoprotein (a) levels with low density lipoprotein apheresis is reported in Daida, Am. J. Card. 1994; 73 (15): 1037-1040.
Lp (a) of serum is an independent factor associated with stenosis of saphenous vein grafts (Hoff, Circulation, 1988; 77 (6): 1238-1243.
SUMMARY OF THE INVENTION The present invention is directed to new uses of compounds I below. The compounds are those of the formula: O O
I I R, - X - S - N - C - Y - R2 | | ORI or a pharmaceutically acceptable salt thereof where: X and Y are selected from oxygen, sulfur and (CR'R ") n, where n is an integer from 1 to 4 and R 'and R" are each independently hydrogen, alkyl, alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, optionally substituted phenyl or R 'and R "together form a spirocycloalkyl or a carbonyl, with the proviso that at least one of the X and Y is - (CR' R ") n - and with the additional condition when X and Y are both (CR'R" n and R 'and R "are hydrogen and n is one, R! and R2 are aryl; R is hydrogen, a linear or branched alkyl of 1; to 8 carbon atoms or benzyl;
Ri and R2 are each independently selected from: (a) phenyl or phenoxy, each of which is unsubstituted or substituted with 1 to 5 substituents selected from; phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched, an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p is zero or one and each of R3 and R4 is selected from hydrogen or a linear or branched alkyl group having from 1 to 4 carbon atoms; (b) 1 - or 2-naphthyl unsubstituted or substituted with 1 to 3 substituents selected from: phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched; an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; hydroxy, phenoxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p, R3 and R4 have the meaning defined above; (c) arylalkyl;
(d) a linear or branched alkyl chain having 1 to 20 carbon atoms and which is saturated or contains 1 to 3 double bonds; or (e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety has from 3 to 6 carbon atoms; with the following conditions: (i) where X is (CH2) n, Y is oxygen and R1 is a substituted phenyl, then R2 is a substituted phenyl; (ii) where Y is oxygen, X is (CH2) n, R2 is phenyl or naphthyl, then Rj is not a straight or branched alkyl chain; and (iii) the following compounds are excluded:
The preferred compounds of the present invention are those of Formula I: wherein Ri is phenyl or is phenyl bisubstituted at positions 2, 6, where R2 is phenyl or phenyl bisubstituted at positions 2, 6, where each of Rj and R2 is phenyl, where each phenyl is bisubstituted at position 2, 6, where Rt is phenyl substituted at positions 2, 6 and R2 is phenyl trisubstituted at positions 2, 4, 6, where Ri is 2, 6-bis (1 - methylethyl) phenyl and R2 is 2,6-bis (1-methylethyl) phenyl or 2,4,6-tris (1-methyl-ethyl) phenyl, where one of Rt and R2 is the group
- (CH2) t -> C5- (CH2) W - R7 I Ro where t is zero or 1 to 4; is zero or 1 to 4 with the proviso that the sum of t and w is not greater than 5; R5 and R1 are each independently selected from hydrogen or alkyl having from 1 to 6 carbon atoms or when R5 is hydrogen, R1 can be selected from the groups defined by R7; and R7 is phenyl or phenyl substituted with 1 to 3 substituents selected from a linear or branched alkyl group having 1 to 6 carbon atoms, straight or branched alkoxy group having 1 to 6 carbon atoms, phenoxy, hydroxy, fluorine , chlorine, bromine, nitro, trifluoromethyl, -COOH, COOalkyl wherein P, R3 and R4 have the meaning defined above.
Also the preferred compounds of the present invention are those of the formula I wherein X is oxygen, sulfur or (CR'R ") n; Y is oxygen, sulfur or (CR'R") n; with the proviso that at least one of the X or Y is (CR'R ") n where n is an integer from 1 to 4 and R 'and R" are each independently hydrogen, linear or branched alkyl of 1 to 6 carbon atoms, optionally substituted phenyl, halogen, hydroxy, alkoxy, acyloxy, cycloalkyl, or R 'and R "together form a carbonyl group or a spirocycloalkyl of 3 to 10 carbons, R is hydrogen, R is phenyl optionally substituted linear or branched alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms;
R2 is optionally substituted phenyl, linear or branched alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, phenoxy optionally substituted with the proviso that only if X is (CR'R ") n Rr can be optionally replaced and only if
Y is (CR'R ") n R2 can optionally be substituted phenoxy and with the additional proviso that at least one of R1 and R2 are phenyl or phenoxy optionally substituted.
The most preferred compounds of the present invention are those of the formula I wherein: X is oxygen; Y is (CR'R ") n where n is an integer from 1 to 2, R is hydrogen, R1 is optionally substituted phenyl, R2 is optionally substituted phenyl or phenoxy, linear or branched alkyl of 1 to 10 carbons or 3-cycloalkyl. at 10 carbons, and R 'and R "are each independently hydrogen, linear or branched alkyl of 1 to 6 carbons, optionally substituted phenyl, halogen, hydroxy, alkoxy, acyloxy, cycloalkyl or R' and R" together form a carbonyl or spirocycloalkyl.
DETAILED DESCRIPTION OF THE INVENTION The compounds useful in the present invention provide a class of sulfamic acid esters N-acyl (or thioesters), N-acyl sulfonamides and carbamic acid esters N
- Sulfonyl (or thioesters) which are inhibitors of ACAT, are now found to be useful in the treatment of cerebrovascular diseases such as seizures, peripheral vascular disease and restenosis. It has been found that the compounds of the present invention are effective in decreasing Lp (a).
In Formula I above, illustrative examples of linear or branched saturated hydrocarbon chains having from 1 to 20 carbon atoms include the methyl, ethyl, n-propyl, isopropyl, n-butyl, iso-butyl, tert groups. butyl, i -pentyl, isopentyl, n-hexyl, n-heptyl, n-octyl, n-undecyl, n-dodecyl, n-hexadecyl, 2,2-dimethyldodecyl, 2 -tetradecyl and n-octadecyl.
Illustrative examples of hydrocarbon chains having 1 to 20 carbon atoms and having 1 to 3 double bonds include ethenyl, 2-propenyl, 2-butenyl, 3-pentyl, 2-octenyl, 5-nonenyl, 4-undecenyl , 5-heptadecenyl, 3-octadecenyl, 9-octadecenyl, 2,2-dimethyl-11-eicosenyl, 9, 12-octadecadienyl and hexadecenyl.
Linear or branched alkoxy groups having from 1 to 6 carbon atoms include, for example, methoxy, ethoxy, n-propoxy, 1-butoxy and pentyloxy.
Illustrative examples of linear or branched alkyl groups having from 1 to 6 carbon atoms as used in formula I include methyl, ethyl, n-propyl, isopropyl, n-pentyl, n-butyl and leu-butyl.
Illustrative examples of the cycloalkyl groups, as used in formula I, include cyclopentyl, cyclohexyl, cyclooctyl, tetrahydronaphthyl and 1- or 2-adamantyl.
The spirocycloalkyl groups are, for example, spirocyclopropyl, spirocyclobutyl, spirocyclopentyl and spirocyclohexyl.
Illustrative examples of the arylalkyl groups are: benzyl, phenethyl, 3-phenylpropyl, 2-phenylpropyl, 4-phenylbutyl, 2-phenylbutyl, 3-phenylbutyl, benzhydryl, 2,2-diphenylethyl and 3,3-diphenylpropyl.
The pharmaceutically acceptable salts of the compounds of the formula I are also included as part of the present invention.
Base salts can be generated from compounds of Formula I by reacting the latter with an equivalent of a suitable pharmaceutically acceptable base followed by evaporation of the solvent used for the reaction and recrystallization of the ally, if required.
The compounds of Formula I can be recovered from the base salt by reacting the salt with an aqueous solution of a suitable acid such as hydrobromic, hydrochloric or acetic.
Suitable bases for forming the base salts of the compounds of this invention include amines such as triethylamine or dibutylamine or alkali metal bases and alkali metal bases. The preferred alkali metal hydroxides and alkali metal hydroxides as salt formers are the hydroxides of lithium, sodium, potassium, magnesium or calcium. Suitable classes of bases for the formation of pharmaceutically acceptable non-toxic salts are well known to practitioners of pharmaceutical formulating techniques. See, for example, Berge, SN, et al. J. Pharm. Sci. 1977; 66: 1-19.
Suitable acids for forming acid salts of the compounds of this invention contain a basic group including, but not necessarily limited to acetic, benzoic, benzensulfonic, tartaric, hydrobromic, hydrochloric, citric, fumaric, gluconic, glucuronic, glutamic, lactic, malic, maleic, methanesulfonic, pamico, salicylic, stearic, succinic, sulfuric and tartaric. Additional acid salts are formed by methods well known in the art.
The compounds of the present invention can also exist in different stereoisomeric forms by virtue of the presence of asymmetric centers in the compounds. The present invention contemplates all stereoisomeric forms of the compounds as well as mixtures thereof, including racemic forms.
In addition, the compounds of this invention can exist in insoluble forms as well as in soluble forms with pharmaceutically acceptable solvents such as water, ethanol and the like. In general, soluble forms are considered equivalent to insoluble forms for the purposes of this invention.
The preferred compounds of the present invention are those where one of the
Ri and R2 are substituted phenyl and still more favored where one of the R, and R2 are phenyl substituted at positions 2, 6. In another preferred copy, R { and R2 are phenyl bisubstituted at positions 2, 6. In another preferred example, Rt is phenyl substituted at the 2, 6 position and R2 is trisubstituted at positions 2, 4, 6.
In another preferred example of the present invention, Ri is 2,6-bis (1-methylethyl) phenyl; and R 2 is 2,6-bis (1-methylethyl) phenyl or 2,4,6-tris (1-methylethyl) phenyl.
Preferred compounds of Formula I include, but are not limited to the following:
Sulfamic acid (phenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-6-tris (1-methylethyl) phenyl] -acetyl] -2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2] , 4, 6-tris (1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl) phenyl] -acetyl] ] - 2, 4, 6 - tris (1-methylethyl) phenyl ester, Sulfamic acid [adamantaneacetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl)] phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, sulfamic acid [[2,6-6-tris (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, Sulfamic acid [decanoyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [dodecanoyl] -2,6-bis (1-methylethyl) phenyl ester, 2, 6-bis (1-methylethyl) -N - [[[2,6- tris (1-methylethyl) phenyl] methyl] sulfonyl-benzeneacetamide, 2,6-bis (1-methylethyl) - N - [[ [2, 4, 6-tris (1-methylethyl) phenyl] methyl] sulfonyl] sodium salt of benzeneacetamide, 2,6-bis (1-methylethyl) phenyl [[[2, 4, 6-tris (1-methylethyl ) phenyl] methyl] sulfonyl] carbamate, 2,6-bis (1-methylethyl) phenyl [[[2,6- tris (1-methylethyl) phenyl] methyl] sulfonyl] sodium salt of carbamate, sulfamic acid ( 1-oxo-3, 3-diphenylpropyl) -2,6-bis (1-methylethyl) phenyl ester,
Sulfamic acid (2,6-dichlorophenyl (acetyl)] - 2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl (acetyl)] - 2,6- bis (1-methylethyl) phenyl ester, Sulfamic acid trans - [(2-phenylcyclopropyl) -carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2,5-dimethoxyphenyl (acetyl)] -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid [2,4,6-trimethoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester,
Sulfamic acid [2,4-6-trimethylphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [3 - thiophenyl (acetyl)] - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid [2 - methoxyphenyl (acetyl)] - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid (oxofenilacetil) - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid [2 - trifluoromethylphenyl (acetyl)] - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid (1 - oxo - 2 - phenylpropyl) - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid (ciclopentilfenilacetil) - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid (cyclohexylacetyl) - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid (diphenylacetyl) - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid (trifenilacetil) - 2, 6 - bis (1 - methylethyl) phenyl ester, sulfamic acid [(1 - phenylcyclopentyl) carbonyl] - 2, 6-bis (1-methylethyl) phenyl ester,
Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2-phenylbutyl) -2,6-bis (1-methylethyl) ) phenyl ester, Sulfamic acid (cyclohexylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2, 2-diphenylpropyl) -2,6-bis (1-methylethyl) phenyl ester,
Sulfamic acid [(9H-fluoren-9-yl) carbonyl] -2,6-bis (1-methylethyl) phenyl ester,
Sulfamic acid (1-oxo-3-phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4,6- tris (1-methylethyl) -phenyl] - 2 - propenyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4,6-tris (1-methylethyl) -phenyl] -propyl] -2,6 - bis (1-methylethyl) phenyl ester, Sulfamic acid [(acetyloxy) [2, 4, 6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methyl-ethyl) -phenyl ester, sulfamic acid [hydroxy [2, 4, 6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [fluoro [2,4,6-tris (1-methylethyl ) - phenyl] acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) sodium salt of phenyl ester, Sulfamic acid [[2,4,6-tris (1-methylethyl) -phenoxy] -acetyl] -2,6-bis (1-methyl-ethyl) -phenyl ester, sulfamic acid [[2,6-bis (1 - methylethyl) - phenoxy] acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2,6-6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (phenyl) phenyl ester,
The ability of the compounds of the present invention to decrease Lp (a) is summarized in Table I below. The procedure is: nine cynomogus male monkeys. { Macaca fascicularis of 4 - 5 kg) are kept in a standard food diet of monkeys (containing less than 5% fat and only trace amounts of cholesterol). The diet is available daily from 9 AM. at 2 PM. These animals carry approximately equal amounts of cholesterol in HDL (47%) and LDL (51%) and have low triglycerides compared to humans (approximately 50 mg / dL). Five weekly blood samples are taken from controlled anesthetized animals and then the animals are dosed with sulfamic acid [[2, 4, 6 - tris - (1-methylethyl) phenyl] acetyl-2,6-bis (1-methyl ethyl) phenyl ester (from here on, the compound) daily before meals (for 3 weeks at 30 mg / kg) when incorporated into oatmeal cakes (Little Debbie Snack Cakes, McKee Foods, Collegedale, Tennessee). Tang glass drinks for breakfast (Kraft General Foods, Inc. White Plains, New York) and additional cream filling is also added to the individual servings. Most of the animals consumed the drug-containing treatment immediately since they were without food during the night. They were not given their daily food until they consumed the treatment. The mean cholesterol values in the plasma (top line) and LP (a) (bottom line) are shown below (all values are in mg / dL). The treatment of the drug was in weeks 6 to 8 and are highlighted in Table I.TABLE I
The average baseline values for cholesterol and Lp (a) are 154 and 16.6 mg / dL, respectively. Using these values, the percentage decreases for cholesterol and for Lp (a) by 28% and 31%, respectively. It is important to note that each animal showed a decrease in cholesterol and Lp (a), that is, there was not one that did not respond to the compound. The decrease in total cholesterol is mainly due to a decrease in LDL cholesterol.
The compounds of the present invention are then useful in pharmaceutical formulations for the treatment of seizures, peripheral vascular disease and restenosis, the compounds of Formulas I or II or the pharmaceutically acceptable salts thereof are administered to patients at levels of dosage of 250 to 3000 mg per day. For a normal adult human of approximately 70 kg of weight, this translates into a dosage of 5 to 40 mg / kg of weight per day. The specific doses employed, however, may vary depending on the requirements of the patient, the severity of the condition being treated and the activity of the compound being used. The determination of optimal doses for a particular situation is within the skills of the technique.
Claims (23)
- CLAIMS. A method for lowering the serum or plasma level of Lp (a) in a mammal in need of such treatment, comprising administering to said mammal an amount effective to decrease the level in the plasma or serum of said Lp ( a) of a compound of the Formula: OO I I O R I or a pharmaceutically acceptable salt thereof where: X and Y are selected from oxygen, sulfur and (CR'R ") n, where n is an integer from 1 to 4 and R 'and R" are each independently hydrogen , alkyl, alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, optionally substituted phenyl or R 'and R "together form a spirocycloalkyl or a carbonyl, with the proviso that at least one of the X and Y is - (CR' R" ) n - and with the additional condition when X and Y are both (CR'R "n and R 'and R" are hydrogen and n is one, Ri and R2 are aryl, R is hydrogen, a linear or branched alkyl of 1 to 8 carbon atoms or benzyl; Rj and R2 are each independently selected from: (a) phenyl or phenoxy, each of which is unsubstituted or substituted with 1 to 5 substituents selected from phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched, an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p is zero or one and each of R3 and R4 is selected from hydrogen or a linear or branched alkyl group having from 1 to 4 carbon atoms; (b) 1 - or 2-naphthyl unsubstituted or substituted with 1 to 3 substituents selected from: phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched; an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; hydroxy, phenoxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p, R3 and R4 have the meaning defined above; (c) arylalkyl; (d) a linear or branched alkyl chain having 1 to 20 carbon atoms and which is saturated or contains 1 to 3 double bonds; or (e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety has from 3 to 6 carbon atoms; with the following conditions: (i) where X is (CH2) n, Y is oxygen and Ri is a substituted phenyl, then R2 is a substituted phenyl; (ii) where Y is oxygen, X is (CH2) n, R2 is phenyl or naphthyl, then R1 is not a straight or branched alkyl chain; and (iii) the following compounds are excluded:
- 2. A method according to Claim 1 where R? It is phenyl.
- 3. A method according to Claim 2 wherein Ri is phenyl-substituted at positions 2, 6.
- 4. A method according to Claim 1 wherein R2 is phenyl.
- 5. A method according to Claim 4 wherein R2 is phenyl-substituted at positions 2, 6.
- 6. A method according to Claim 1 where each of R { and R2 is phenyl.
- 7. A method according to claim 6 wherein each phenyl is bisubstituted at positions 2, 6.
- 8. A method according to Claim 1 wherein Rr is phenyl substituted at positions 2, 6 and R2 is phenyl trisubstituted at positions 2, 4, 6.
- 9. A method according to Claim 1 wherein Rj is 2,6-bis (1-methylethyl) phenyl and R2 is 2,6-bis (1-methylethyl) phenyl or 2,4,6-tris- (1-methylethyl) phenyl
- 10. A method according to Claim 1 wherein R j is phenyl or phenyl is substituted at positions 2, 6, where R 2 is phenyl or phenyl bisubstituted at positions 2, 6, where each of R t and R 2 is phenyl, where each phenyl is bisubstituted at position 2, 6, where Rt is phenyl substituted at positions 2, 6 and R2 is phenyl trisubstituted at positions 2, 4, 6, where Ri is 2,6-bis (1-methylethyl) phenyl and R2 is 2, 6-bis (1-methylethyl) phenyl or 2, 4, 6 -. 6 - tris (1-methyl-ethyl) phenyl, where one of Ri and R2 is the group - (CH2) t - C - (CH2) w - R7 where t is zero or 1 to 4; w is zero or 1 to 4 with the proviso that the sum of t and w is not greater than 5; R5 and R are each independently selected from hydrogen or alkyl having from 1 to 6 carbon atoms or when R5 is hydrogen, R can be selected from the groups defined by R7; and R7 is phenyl or phenyl substituted with 1 to 3 substituents selected from a linear or branched alkyl group having 1 to 6 carbon atoms, straight or branched alkoxy group having 1 to 6 carbon atoms, phenoxy, hydroxy, fluorine , chlorine, bromine, nitro, trifluoromethyl, -COOH, COOalkyl wherein the alkyl has from 1 to 4 carbon atoms or - (CH2) pNR3R4 where P, R3 and R4 have the meaning defined above.
- 11. A method according to Claim 1 wherein: X is oxygen, sulfur or (CR'R ") n; Y is oxygen, sulfur or (CR'R") n; with the proviso that at least one of the X or Y is (CR'R ") n where n is an integer from 1 to 4 and R 'and R" are each independently hydrogen, linear or branched alkyl of 1 to 6 carbon atoms, optionally substituted phenyl, halogen, hydroxy, alkoxy, acyloxy, cycloalkyl, or R 'and R "together form a carbonyl group or a spirocycloalkyl of 3 to 10 carbons, R is hydrogen, Ri is phenyl optionally substituted, linear or branched alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 10 carbon atoms, R2 is optionally substituted phenyl, linear or branched alkyl of 1 to 10 carbon atoms, cycloalkyl of 3 to 8 carbon atoms, phenoxy optionally replaced with the condition that only if X is (CR'R ") n R! can optionally be substituted and only if Y is (CR'R ") n R2 can optionally be substituted phenoxy and with the additional proviso that at least one of Ri and R2 are optionally substituted phenyl or phenoxy.
- 12. A method according to Claim 1 wherein: X is oxygen; Y is (CR'R ") n where n is an integer from 1 to 2; R is hydrogen; Ri is optionally substituted phenyl; R2 is optionally substituted phenyl or phenoxy, linear or branched alkyl of 1 to 10 carbons or cycloalkyl of 3 to 10 carbons; and R 'and R "are each independently hydrogen, linear or branched alkyl of 1 to 6 carbons, optionally substituted phenyl, halogen, hydroxy, alkoxy, acyloxy, cycloalkyl or R' and R" together form a carbonyl or spirocycloalkyl.
- 13. A method according to Claim 1 wherein the compound used is selected from: Sulfamic acid (phenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6,6-tris (1-methylethyl ) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,4,6-tris (1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methylethyl) phenyl ester, sulfamic acid [[2,6-bis] 1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methylethyl) phenyl ester, sulfamic acid [adamantaneacetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2, 6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, Sulfamic acid [[2,6,6-tris (1-methylethyl) phenyl]] acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, sulfamic acid [decanoyl] -2,6-bis (1-methyl) lethyl) phenyl ester, Sulfamic acid [dodecanoyl] -2,6-bis (1-methylethyl) phenyl ester, 2,6-bis (1-methylethyl) - N - [[[2, 4, 6-tris (1 - methylethyl) phenyl] methyl] sulfonyl] benzeneacetamide, 2,6-bis (1-methylethyl) - N - [[[2,4-, 6-tris (1-methylethyl) phenyl] methyl] sulfonyl] sodium salt of benzeneacetamide, 2, 6-bis (1-methylethyl) phenyl [[[2,6- tris (1-methylethyl) phenyl] methyl] sulfonyl] carbamate, 2,6-bis (1-methylethyl) phenyl] [[[2, 4, 6-tris (1-methylethyl) phenyl] methyl] sulfonyl] carbamate sodium salt, Sulfamic acid (1-oxo-3,3-diphenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl (acetyl)] - 2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl (acetyl)] - 2,6- bis (1-methylethyl) phenyl ester, Sulfamic acid trans - [(2-phenylcyclopropyl) -carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2,5-dimethoxyphenyl (acetyl)] -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid [2,4,6-trimethoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [2,4,6-trimethylphenyl (acetyl)] -2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [3-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-methoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (oxophenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-trifluoromethylphenyl (acetyl) ] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2-phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclopentylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclohexylacetyl) - 2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid (diphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (triphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester , Sulfamic acid [(1-phenylcyclopentyl) carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) ) phenyl ester, Sulfamic acid (1-oxo-2-phenylbutyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclohexylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2, 2-diphenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [(9H-fluoren-9-yl) carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-3-phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4,6- tris (1-methylethyl) -phenyl] - 2 - propenyl] - 2, 6 - bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4, 6-tris (1-methylethyl) -phenyl] propyl] -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid [(acetyloxy) [2, 4, 6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methyl-ethyl) -phenyl ester, sulfamic acid [hydroxy] , 4,6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [fluoro [2,4,6-tris (1-methylethyl) -phenyl]] acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) phenyl ester sodium salt, Acid Sulfamic [[2, 4, 6-tris (1-methylethyl) -phenoxy] acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl) -phenoxy] ] acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2,6-6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (phenyl) phenyl ester,
- 14. A method according to Claim 1 wherein the sulfamic acid [[2,4,6-tris (1-methylethyl) -phenyl] acetyl] -2,6-bis (1-methylethyl) phenyl ester is administered. ? S.
- A method for treating peripheral vascular disease which comprises "administration to a mammal in need of such treatment of a therapeutically effective amount of a compound of the Formula: O O I I R, - X - S - N - C - Y - R2 I I O R I or a pharmaceutically acceptable salt thereof where: X and Y are selected from oxygen, sulfur and (CR'R ") n, where n is an integer from 1 to 4 and R 'and R" are each independently hydrogen , alkyl, alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, optionally substituted phenyl or R 'and R "together form a spirocycloalkyl or a carbonyl, with the proviso that at least one of the X and Y is - (CR' R" ) n - and with the additional condition when X and Y are both (CR'R "n and R 'and R" are hydrogen and n is one, R! and R2 are aryl; R is hydrogen, a linear or branched alkyl of 1 to 8 carbon atoms or benzyl; R1 and R2 are each independently selected from: (a) phenyl or phenoxy, each of which is unsubstituted or substituted with 1 to 5 substituents selected from; phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched, an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p is zero or one and each of R3 and R4 is selected from hydrogen or a linear or branched alkyl group having from 1 to 4 carbon atoms; (b) 1 - or 2-naphthyl unsubstituted or substituted with 1 to 3 substituents selected from: phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched; an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; hydroxy, phenoxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p, R3 and R4 have the meaning defined above; (c) arylalkyl; (d) a linear or branched alkyl chain having 1 to 20 carbon atoms and which is saturated or contains 1 to 3 double bonds; or (e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety has from 3 to 6 carbon atoms; with the following conditions: (i) where X is (CH2) n, Y is oxygen and Ri is a substituted phenyl, then R2 is a substituted phenyl; (ii) where Y is oxygen, X is (CH2) n, R2 is phenyl or naphthyl, then Rj is not a straight or branched alkyl chain; and (iii) the following compounds are excluded:
- 16. A method according to Claim 15 wherein the compound administered is selected from: Sulfamic acid (phenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6,6-tris (1-methylethyl ) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,4,6-tris (1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methylethyl) phenyl ester, sulfamic acid [[2,6-bis] 1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methylethyl) phenyl ester, sulfamic acid [adamantaneacetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2, 6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, Sulfamic acid [[2,6,6-tris (1-methylethyl) phenyl]] acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, sulfamic acid [decanoyl] -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid [dodecanoyl] -2,6-bis (1-methylethyl) phenyl ester, 2,6-bis (1-methylethyl) - N - [[[2, 4, 6-tris (1 - methylethyl) phenyl] methyl] sulfonyl] benzeneacetamide, 2,6-bis (1-methylethyl) - N - [[[2,4-, 6-tris (1-methylethyl) phenyl] methyl] sulfonyl] sodium salt of benzeneacetamide, 2, 6-bis (1-methylethyl) phenyl [[[2,6- tris (1-methylethyl) phenyl] methyl] sulfonyl] carbamate, 2,6-bis (1-methylethyl) phenyl] [[[2, 4, 6-tris (1-methylethyl) phenyl] methyl] sulfonyl] carbamate sodium salt, Sulfamic acid (1-oxo-3,3-diphenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl (acetyl)] - 2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl (acetyl)] - 2,6- bis (1-methylethyl) phenyl ester, Sulfamic acid trans - [(2-phenylcyclopropyl) -carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2,5-dimethoxyphenyl (acetyl)] -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid [2,4,6-trimethoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [2,4,6-trimethylphenyl (acetyl)] -2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [3-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-methoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (oxophenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-trifluoromethylphenyl (acetyl) ] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2-phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclopentylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclohexylacetyl) - 2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid (diphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (triphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester , Sulfamic acid [(1-phenylcyclopentyl) carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) ) phenyl ester, Sulfamic acid (1-oxo-2-phenylbutyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclohexylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2, 2-diphenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [(9H-fluoren-9-yl) carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-3-phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4,6- tris (1-methylethyl) -phenyl] - 2 - propenyl] - 2, 6 - bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4, 6-tris (1-methylethyl) -phenyl] propyl] -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid [(acetyloxy) [2, 4, 6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methyl-ethyl) -phenyl ester, Sulfamic acid [hydroxy [2, 4, 6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [fluoro [2, 4, 6-tris ( 1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) salt sodium phenyl ester, Sulfamic acid [[2,4,6-tris (1-methylethyl) -phenoxy] acetyl] -2,6-bis (1-methyl ethyl) phenyl ester, sulfamic acid [[2,6-bis] (1-methylethyl) -phenoxy] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2,6-6-tris (1-methylethyl) -phenyl] -acetyl] -2,6- bis (phenyl) phenyl ester,
- 17. A method for treating peripheral vascular disease comprising administration to a patient in need of such treatment of a compound called sulfamic acid [[2,4,6-tris (1-methylethyl) -phenyl] -acetyl] -2,6- bis (1-methylethyl) phenyl ester.
- 18. A method for treating restenosis comprising administration to a mammal in need of said treatment of a therapeutically effective amount of a compound of the Formula: O O I I O R I or a pharmaceutically acceptable salt thereof where: X and Y are selected from oxygen, sulfur and (CR'R ") n, where n is an integer from 1 to 4 and R 'and R" are each independently hydrogen , alkyl, alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, optionally substituted phenyl or R 'and R "together form a spirocycloalkyl or a carbonyl, with the proviso that at least one of the X and Y is - (CR' R" ) n - and with the additional condition when X and Y are both (CR'R "n and R 'and R" are hydrogen and n is one, Rj and R2 are aryl, R is hydrogen, a linear or branched alkyl of 1 to 8 carbon or benzyl atoms: Rj and R2 are each independently selected from: (a) phenyl or phenoxy, each of which is unsubstituted or substituted with 1 to 5 substituents selected from; phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched, an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p is zero or one and each of R3 and R4 is selected from hydrogen or a linear or branched alkyl group having from 1 to 4 carbon atoms; (b) 1 - or 2-naphthyl unsubstituted or substituted with 1 to 3 substituents selected from: phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched; an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; hydroxy, phenoxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p, R3 and R4 have the meaning defined above; (c) arylalkyl; (d) a linear or branched alkyl chain having 1 to 20 carbon atoms and which is saturated or contains 1 to 3 double bonds; or (e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety has from 3 to 6 carbon atoms; with the following conditions: (i) where X is (CH2) ", Y is oxygen and Rj is a substituted phenyl, then R2 is a substituted phenyl; (ii) where Y is oxygen, X is (CH2) n, R2 is phenyl or naphthyl, then Rj is not a straight or branched alkyl chain; and (iii) the following compounds are excluded:
- 19. A method for treating restenosis according to Claim 18 wherein the compound administered is selected from: Sulfamic acid (phenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2, 4, 6-tris] (1-Methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis ( 1-methylethyl) phenyl ester, Sulfamic acid [[2,4,6-tris (1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methyl ethyl) phenyl ester, sulfamic acid [[2, 6-bis (1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methylethyl) phenyl ester, sulfamic acid [adamantaneacetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2,6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, sulfamic acid [[2,6,6-tris (1-methylethyl]] ) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, sulfamic acid [from canoil] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [dodecanoyl] -2,6-bis (1-methylethyl) phenyl ester, 2,6-bis (1-methylethyl) -N - [[ [2, 4,6-tris (1-methylethyl) phenyl] methyl] sulfonylbenzeneacetamide, 2,6-bis (1-methylethyl) - N - [[[2,4,6- tris (1-methylethyl) phenyl] methyl] sulfonyl ] sodium salt of benzenacetamide, 2,6-bis (1-methylethyl) phenyl [[[2,4,6-tris (1-methylethyl) phenyl] methyl] sulfonyl] carbamate, 2,6-bis (1-methylethyl) ) phenyl [[[2, 4, 6-tris (1-methylethyl) phenyl] methyl] sulfonyl] sodium salt of carbamate, sulfamic acid (1-oxo-3, 3-diphenylpropyl) -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl (acetyl)] - 2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl (acetyl)) - 2,6- bis (1-methylethyl) phenyl ester, Sulfamic acid trans - [(2-phenylcyclopropyl) -carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2,5-dimethoxyphenyl (acetyl)] -2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2,4,6-trimethoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, S-acid [2, 4, 6-trimethylphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [2-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester , Sulfamic acid [3-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-methoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Acid Sulfamic (oxophenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-trifluoromethylphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2) - phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclopentylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclohexylacetyl) -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid (diphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (triphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [(1-phenylcyclopentyl carbonyl] - 2, 6 - bis (1-methylethyl) phenyl ester, Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2-phenylbutyl) - 2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclohexylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2, 2-diphenylpropyl) -2,6- bis (1-methylethyl) phenyl ester, Sulfamic acid [(9H-fluoren-9-yl) carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-3-phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4,6- tris (1-methylethyl) -phenyl] - 2 - propenyl] - 2, 6 - bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4, 6-tris (1-methylethyl) -phenyl] propyl] -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid [(acetyloxy) [2, 4, 6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methyl-ethyl) -phenyl ester, sulfamic acid [hydroxy] , 4,6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [fluoro [2,4,6-tris (1-methylethyl) -phenyl]] acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) phenyl ester sodium salt, Acid Sulfamic [[2, 4, 6-tris (1-methylethyl) -phenoxy] acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl) -phenoxy] ] acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2,6-6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (phenyl) phenyl ester,
- 20. A method for treating cerebrovascular disease comprising administration to a patient in need of such treatment of a compound called sulfamic acid [[2,4,6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis. (1-methylethyl) phenyl ester.
- 21. A method for treating cerebrovascular disease comprising administering to a mammal in need of said treatment a therapeutically effective amount of a compound of the Formula: O O I I R, - X - S - N - C - Y - R2 O R or a pharmaceutically acceptable salt thereof where: X and Y are selected from oxygen, sulfur and (CR'R ") n, where n is an integer from 1 to 4 and R 'and R" are each independently hydrogen , alkyl, alkoxy, halogen, hydroxy, acyloxy, cycloalkyl, optionally substituted phenyl or R 'and R "together form a spirocycloalkyl or a carbonyl, with the proviso that at least one of the X and Y is - (CR' R" ) n - and with the additional condition when X and Y are both (CR'R "n and R 'and R" are hydrogen and n is one, R and R2 are aryl, R is hydrogen, a linear or branched alkyl of 1 to 8 carbon atoms or benzyl; Rj and R2 are each independently selected from: (a) phenyl or phenoxy, each of which is unsubstituted or substituted with 1 to 5 substituents selected from; phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched, an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; phenoxy, hydroxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p is zero or one and each of R3 and R4 is selected from hydrogen or a linear or branched alkyl group having from 1 to 4 carbon atoms; (b) 1 - or 2-naphthyl unsubstituted or substituted with 1 to 3 substituents selected from: phenyl, an alkyl group having 1 to 6 carbon atoms and which is linear or branched; an alkoxy group having 1 to 6 carbon atoms and which is linear or branched; hydroxy, phenoxy, fluorine, chlorine, bromine, nitro, trifluoromethyl, - COOH, - COOalkyl where the alkyl has from 1 to 4 carbon atoms and is linear or branched, - (CH2) pNR3R4 where p, R3 and R4 have the meaning defined above; (c) arylalkyl; (d) a linear or branched alkyl chain having 1 to 20 carbon atoms and which is saturated or contains 1 to 3 double bonds; or (e) adamantyl or a cycloalkyl group wherein the cycloalkyl moiety has from 3 to 6 carbon atoms; with the following conditions: (i) where X is (CH2) n, Y is oxygen and Rj is a substituted phenyl, then R2 is a substituted phenyl; (ii) where Y is oxygen, X is (CH2) n, R2 is phenyl or naphthyl, then Rj is not a straight or branched alkyl chain; and (iii) the following compounds are excluded:
- 22. A method for treating cerebrovascular disease according to Claim 21 wherein the compound administered is selected from: Sulfamic acid (phenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2, 4, 6 - tris (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2,6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [[2,6- tris (1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methylethyl) phenyl ester, sulfamic acid [[2 , 6-bis (1-methylethyl) phenyl] -acetyl] -2,4,6-tris (1-methylethyl) phenyl ester, Sulfamic acid [adamantaneacetyl] -2,6-bis (1-methylethyl) phenyl ester, Acid Sulfamic [[2,6-bis (1-methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, Sulfamic acid [[2, 4, 6-tris (1 - methylethyl) phenyl] -acetyl] -2,6-bis (1-methylethyl) phenyl ester sodium salt, Ac Sulfamic [decanoyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [dodecanoyl] -2,6-bis (1-methylethyl) phenyl ester, 2,6-bis (1-methylethyl) - N - [[[2, 4, 6-tris (1-methylethyl) phenyl] methyl] sulfonyl] benzeneacetamide, 2,6-bis (1-methylethyl) - N - [[[2, 4, 6-tris (1 - methylethyl) phenyl] methyl] sulfonyl] sodium salt of benzeneacetamide, 2,6-bis (1-methylethyl) phenyl [[[2,4,6-tris (1-methylethyl) phenyl] methyl] sulfonyl] carbamate, 2, 6-bis (1-methylethyl) phenyl [[[2,4-, 6-tris (1-methylethyl) phenyl] methyl] sulfonyl] sodium salt of carbamate, sulfamic acid (1-oxo-3, 3-diphenylpropyl) - 2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (2,6-dichlorophenyl) (acetyl) ] - 2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid trans - [(2-phenylcyclopropyl) -carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2,5-dimethoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [2,4,6-trimethoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2,4,6-trimethylphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [3-thiophenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-methoxyphenyl (acetyl)] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (oxophenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [2-trifluoromethylphenyl (acetyl) ] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2-phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclopentylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (cyclohexylacetyl) - 2, 6-bis (1-methylethyl) phenyl ester, Sulfamic acid (diphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (triphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester , Sulfamic acid [(1-phenylcyclopentyl) carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2-phenylbutyl) -2,6-bis (1-methylethyl) ) phenyl ester, Sulfamic acid (cyclohexylphenylacetyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-2, 2-diphenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [(9H-fluoren-9-yl) carbonyl] -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid (1-oxo-3-phenylpropyl) -2,6-bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4, 6-tris (1-methylethyl) -phenyl] -2-propenyl] -2,6 - bis (1-methylethyl) phenyl ester, Sulfamic acid [1-oxo-3- [2, 4, 6-tris (1-methylethyl) -phenyl] propyl] -2,6-bis (1 - methylethyl) phenyl ester, Sulfamic acid [(acetyloxy) [2, 4, 6-tris (1-methylethyl) -phenyl] acetyl] -2, 6-bis (1-methyl ethyl) phenyl ester, Sulfamic acid [hydroxy [2, 4, 6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methyl-ethyl) -phenyl ester, Sulfamic acid [fluoro [2, 4, 6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis (1-methyl-ethyl) -phenyl ester, sulfamic acid (3-methyl-1-oxo-2-phenylpentyl) - 2, 6-bis (1-methylethyl) phenyl ester sodium salt, Sulfamic acid [[2, 4, 6-tris (1-methylethyl) -phenoxy] acetyl] -2,6-bis (1-methyl-ethyl) -phenyl ester, Sulfamic acid [[2,6-bis (1-methylethyl) -phenoxy] acetyl] -2,6-bis (1-methylethyl) phenyl ester, sulfamic acid [[2,6,6-tris (1-methylethyl]] ) - phenyl] acetyl] -2,6-bis (phenyl) phenyl ester,
- 23. A method for treating cerebrovascular disease comprising administration to a patient in need of such treatment of a compound called sulfamic acid [[2,4,6-tris (1-methylethyl) -phenyl] -acetyl] -2,6-bis. (1-methylethyl) phenyl ester. EXTRACT OF THE INVENTION The present invention is directed to new therapeutic uses of the compounds of the Formula (I) wherein X and Y are oxygen, sulfur or (CR'R ") n where n is 1 to 4, R is hydrogen, alkyl or benzyl, Rj and R2 are phenyl, substituted phenyl, naphthyl, substituted naphthyl, Aralkyl group, an alkyl, adamantyl or a cycloalkyl group The uses are for cerebrovascular diseases such as attacks, peripheral vascular diseases and restenosis. I I R? -X-S-N-C-Y-R2 I I O R I
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US61136695A | 1995-08-04 | 1995-08-04 | |
| US003031 | 1995-08-04 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MX9709275A MX9709275A (en) | 1998-03-29 |
| MXPA97009275A true MXPA97009275A (en) | 1998-10-15 |
Family
ID=
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR100449604B1 (en) | Method and Pharmaceutical Composition for Regulating Lipid Concentration | |
| US4900757A (en) | Hypocholesterolemic and antiatherosclerotic uses of bix(3,5-di-tertiary-butyl-4-hydroxyphenylthio)methane | |
| NZ545806A (en) | Compositions and methods for lowering plasma lipoprotein(A) and risk factors of cardiovascular diseases | |
| KR20080059164A (en) | Methods and formulations for modulating lyn kinase activity and treating related disorders | |
| US5686450A (en) | Use of N,N'-bis(mercaptoacetyl) hydrazine derivatives as anticataract agents | |
| EP0841913B1 (en) | Use of sulfamic acid derivatives, acyl sulfonamides or sulfonyl carbamates for the manufacture of a medicament for lowering lipoprotein levels | |
| JP2001508795A (en) | Methods for preventing or reducing the risk of developing cardiovascular disease using MTP inhibitors alone or in combination with other cholesterol-lowering drugs | |
| WO1992003130A1 (en) | Use of aryl hydroxyurea compounds for the treatment of atherosclerosis | |
| MXPA97009275A (en) | Use of derivatives of sulfamic acid, acil sulfonamides or sulfonil carbamates for the manufacture of a medicinal product to reduce delipoprotei levels | |
| JP4824573B2 (en) | Pharmaceutical compositions for these treatments in patients with renal failure, kidney disease or disorder, especially in diabetic patients | |
| RU2093153C1 (en) | 5-[2-(tert-butylamino)-1-hydroxyethyl]-meta-phenylene-bis-(di- -methylcarbamate) (bambuterin) as hypolipidemic preparation and pharmaceutical composition based on bambuterin | |
| US4689328A (en) | Process for controlling hyperlipidemia | |
| CN114615979A (en) | Valfelast for the treatment of autism spectrum disorders | |
| US20100041716A1 (en) | Nitroxides for use in treating or preventing hypercholesterolemia | |
| US20090209613A1 (en) | Use of allymercaptocaptopril for treating or preventing obesity and obesity related diseases | |
| JPH0311022A (en) | Drug composition | |
| WO1996022096A1 (en) | Pharmaceutical compositions containing bisaramil inhibiting radical production and process for preparing same | |
| JP2008024699A (en) | Prophylactic or therapeutic agent for corneal/conjunctival disorder comprising fumaric acid derivative as active ingredient |